Drug intelligence / Profile preview

temsirolimus + vinorelbine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

Temsirolimus + vinorelbine is a combination therapy consisting of temsirolimus, an mTOR inhibitor, and vinorelbine, a vinca alkaloid chemotherapeutic agent. Temsirolimus works by blocking some of the enzymes needed for cell growth, specifically targeting the mTOR pathway. Vinorelbine disrupts microtubule assembly, preventing cell division. This combination has shown synergistic effects in clinical trials and has been studied particularly for the treatment of recurrent or refractory rhabdomyosarcoma.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on temsirolimus + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on temsirolimus + vinorelbine.

Explore the full profile